Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label, Safety and Efficacy Study of High Dose Melphalan Hydrochloride for Injection for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation

NCT06425276 is registered in ClinicalTrials.gov with CASI Pharmaceuticals (China) Co., Ltd. as lead sponsor.

NCT NCT06425276
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06425276 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label, Safety and Efficacy Study of High Dose Melphalan Hydrochloride for Injection for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation
Lead sponsor
CASI Pharmaceuticals (China) Co., Ltd.
Phase
Phase 4
Overall status
Completed
Start date
July 24, 2020
Completion date
September 18, 2021
Enrollment
67 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma